ESMO 2023 BioNTech Data
BNT314/GEN10591 - Designed to Boost Antitumor Immune
Response Through EpCAM-Dependent 4-1BB Agonistic Activity
Antitumor activity in human EpCAM-transgenic mice.
Fellermeier-Kopf et al. Presented at ESMO 2023. #1072P
Tumor volume (mm³)
Tumor volumes over time
1,000
800
600
400
200
Percent survival
Kaplan-Meier analysis of survival
100
80
60
60
10
10
20
0
0
7
14
21
28
Days after tumor inoculation
B ] **
****
mbslgG2a-hEpCAM xm4-1BB
Isotype control
0
0 7
14 21 28 35 42 49
Days after tumor inoculation
56
63
mbslgG2a-hEpCAM xm4-1BB
Isotype control
Results suggest that BNT314/GEN1059 may boost antitumor immunity in cancer patients with EpCAM + tumors.
] **
The clinical safety and preliminary antitumor activity of DuoBody-EpCAMx4-1BB will be investigated in patients with solid tumors in a
first-in-human trial.
1. BNT314 (GEN1059) is partnered with Genmab based on 50/50 sharing of costs and profits..
EpCAM
epithelial cell adhesion molecule
5
BIONTECHView entire presentation